How Much BPC-157 Should You Take? A Practical Dosing Guide

BPC-157 at a glance:

• Drug class: Research peptide (not FDA-approved)
• Route: subcutaneous or oral in research; commonly self-administered as injection by users (not endorsed)
• Typical frequency: studied protocols vary; most published animal work uses daily dosing
• Half-life: approximately 4 hours (oral, in animal models)

Dosing BPC-157 correctly isn't complicated, but the details matter. The standard schedule is studied protocols vary; most published animal work uses daily dosing via subcutaneous or oral in research; commonly self-administered as injection by users (not endorsed), and the key decisions happen during titration.

Standard Dosing Schedule for BPC-157

BPC-157 has no established human dosing. Animal studies typically use 10 mcg/kg per day. There are no published well-controlled human trials.

The typical schedule for BPC-157 is studied protocols vary; most published animal work uses daily dosing via subcutaneous or oral in research; commonly self-administered as injection by users (not endorsed). Half-life of approximately 4 hours (oral, in animal models) explains why this schedule works — the drug stays active long enough to support that interval.

Titration: Why Starting Low Matters

For this class of compound, gradual titration is the standard approach. The starting doses listed above are not therapeutic — they exist to let the body adapt and to reduce gastrointestinal symptoms .

A typical titration plan for BPC-157 holds each dose step for at least four weeks before moving up. Faster titration is associated with more dropouts due to side effects.

Missed Doses

If a dose of BPC-157 is missed: for daily schedules, the rule of thumb is to take it as soon as remembered if within a defined window, otherwise skip it and resume the regular schedule. The exact window depends on the half-life (approximately 4 hours (oral, in animal models)) and the specific product label. Never double up to make up for a missed dose.

Dose Adjustments

Dose adjustments may be needed for the following:

• Significant weight loss or weight gain
• Side-effect intolerance at the current step
• Changes in renal or hepatic function
• Drug interactions (particularly relevant for any concurrent medications)

We cover the side-effect side of dose decisions in BPC-157 side effects and the cost angle of dose escalation in BPC-157 cost.

What the Trials Used

Published trial data for BPC-157 comes primarily from: Sikiric et al. (2020, Pharmaceuticals) — review of preclinical evidence. No completed human RCTs.

That data drives the labeled dosing range, which is what physicians prescribe by.

Special Populations

The dosing guidance above applies to general adult use. Special populations — pregnancy, pediatric, severe renal impairment, hepatic dysfunction, elderly with frailty — require individualized assessment that this page can't substitute for.

For BPC-157: the standard contraindications for this drug class apply.

Bottom Line

The single biggest dosing mistake we see with BPC-157 is impatience — skipping titration steps to get to the goal dose faster. It almost always backfires.

Frequently Asked Questions

Related Reading

• What Is BPC-157? Everything You Should Know Before Starting
• Is BPC-157 Safe? An Honest Look at the Side-Effect Profile
• BPC-157 Results: What the Real Numbers Show in 2026
• How Much Does BPC-157 Really Cost? The Honest Breakdown
• BPC-157 Cycle and Protocol: What Researchers Actually Use
• BPC-157 Transformation Timeline: Month 1 Through Year 1

Sources

• Goldstein AL et al. Thymosin β4: A Multi-Functional Regenerative Peptide. Annals NY Acad Sci 2012;1269:1.
• Sosne G et al. Thymosin Beta 4: A Potential Novel Therapy for Neurotrophic Keratopathy. Expert Opinion 2015;15:663.
• Sikiric P et al. Stable Gastric Pentadecapeptide BPC 157 — Major Wound-Healing Properties. Pharmaceuticals 2020;13:155.

This page is informational only and is not medical advice. We do not provide guidance for self-administration of compounds that are not FDA-approved.